Related Experiment Videos
Radionuclide development at BNL for nuclear medicine therapy
L F Mausner1, K L Kolsky, V Joshi
1Brookhaven National Laboratory, Medical Department, Upton, NY 11973-5000, USA.
Summary
Medium energy beta-emitting radionuclides like Scandium-47 (47Sc) show promise for radioimmunotherapy. This study details the production and development of 47Sc and other therapeutic radioisotopes.
Area of Science:
- Nuclear Medicine
- Radiochemistry
- Medical Physics
Background:
- Radioimmunotherapy utilizes radionuclides for targeted cancer treatment.
- Medium energy beta emitters with multi-day half-lives are ideal for this application.
- Key radionuclides include 47Sc, 67Cu, 153Sm, 188Re, and 199Au.
Purpose of the Study:
- To summarize the production of 67Cu, 153Sm, and 199Au at Brookhaven National Laboratory (BNL).
- To detail the development of 47Sc as a promising radioimmunotherapy agent.
- To review the development of 117mSn for bone pain palliation.
Main Methods:
- Production of radionuclides 67Cu, 153Sm, and 199Au at BNL.
- Detailed development and characterization of 47Sc.
- Review of production and application methods for 117mSn.
Main Results:
- Established production methods for 67Cu, 153Sm, and 199Au.
- Significant progress in the development of 47Sc for therapeutic applications.
- Successful application of 117mSn in bone pain palliation.
Conclusions:
- 47Sc is a highly promising radionuclide for radioimmunotherapy.
- BNL has capabilities for producing key therapeutic radionuclides.
- Continued development of targeted radiotherapeutics is crucial for cancer treatment.